Glaxosmithkline, LLC
Glaxosmithkline, LLC, doing business as Glaxosmithkline, is a foreign-owned, for-profit pharmaceutical company headquartered in Durham, North Carolina. The company provides a wide range of pharmaceutical products to federal government agencies, with a primary focus on vaccines, antiviral medications, and medical countermeasures. Glaxosmithkline has established itself as a critical supplier to various federal agencies, offering influenza vaccines, COVID-19 related pharmaceutical products, and specialized medical treatments across multiple sectors of government healthcare and emergency preparedness.
Through federal contract awards, Glaxosmithkline has consistently supplied vaccines and pharmaceutical products to numerous federal agencies. The company has been awarded multiple delivery order contracts with the Department of Justice Bureau of Prisons, Department of Veterans Affairs, Centers for Disease Control and Prevention, and the Department of Health and Human Services. These contracts primarily involve providing influenza vaccines for correctional facilities, VA medical centers, and other federal healthcare systems. The contracts are typically firm fixed-price delivery orders with no set-aside designations, covering vaccine types including Fluarix Trivalent and Quadrivalent, as well as antiviral medications like Zanamivir. Notable contract values range from small orders of a few thousand dollars to larger contracts exceeding $15 million, demonstrating Glaxosmithkline's extensive capabilities in supplying pharmaceutical products to government agencies.
In the realm of federal grant awards, Glaxosmithkline has been involved in targeted research and development efforts. A notable sub-grant award from the Trustees of Boston University focused on developing a small molecule targeting FimH, an adhesive protein found in E. Coli bacteria. This research aimed to explore treatment options for urinary tract infections by preventing E. Coli from binding to the bladder wall. The grant supported early clinical development, including exploring the safety, tolerability, and pharmacokinetics of the FimH antagonist, and facilitating the scale-up of active pharmaceutical ingredient manufacturing and drug product development.
Glaxosmithkline holds multiple significant Indefinite Delivery Contracts (IDVs) with federal agencies, particularly with the Centers for Disease Control and Prevention and the Department of Veterans Affairs. These IDVs cover a broad range of vaccine procurement, including adult and pediatric influenza vaccines, standard adult vaccines, and Vaccines for Children (VFC) program supplies. The company has secured multiple-award IDVs with ceiling values ranging from $13.9 million to over $1.3 billion, covering vaccine types such as hepatitis A and B, HPV, pneumococcal, and meningococcal vaccines. Additionally, Glaxosmithkline maintains a Federal Supply Schedule contract with a maximum ceiling of $3.9 billion, allowing for pharmaceutical product procurement across various government agencies. These contract vehicles demonstrate the company's extensive capabilities in supporting national immunization efforts and medical supply chains.
FRHTPHMZMX47 325412
Not listed 410 Blackwell St, Durham, NC 27701, USA
10/25/10 1/15/26 Grifols USA LLC
Grifols USA LLC is a global healthcare company specializing in the development, manufacturing, and distribution of plasma-derived medicines, transfusion medicine products, and pharmaceutical supplies. As a large, for-profit organization registered in SAM.gov since 2001, the company has established itself as a critical supplier of specialized pharmaceutical products to various federal agencies. The company's primary focus for federal contracts centers on providing essential medical products, particularly PROLASTIN-C, an alpha1-proteinase inhibitor used to treat alpha1-antitrypsin deficiency, as well as a comprehensive range of vaccines.
Through its federal contract awards, Grifols USA LLC has consistently supplied pharmaceuticals and vaccines to multiple federal agencies, primarily the Department of Veterans Affairs (VA), Centers for Disease Control and Prevention (CDC), and Department of Justice's Bureau of Prisons. The company's contract awards predominantly involve delivery orders for PROLASTIN-C and PROLASTIN liquid medications, with contract values ranging from approximately $7,000 to $502,000. These contracts are typically firm fixed-price delivery orders issued under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) and are not designated with any set-aside provisions. The contracts consistently support healthcare programs across various VA Veterans Integrated Service Networks and federal medical facilities, demonstrating Grifols' capability to provide critical pharmaceutical products to support federal healthcare initiatives.
Grifols USA LLC holds several significant indefinite delivery vehicles (IDVs) that underscore its importance in federal pharmaceutical procurement. The most notable is a $1.38 billion Federal Supply Schedule contract with the VA for Pharmaceuticals and Drugs, which includes a $107.5 million Blanket Purchase Agreement specifically for PROLASTIN-C. Additionally, the company maintains multiple CDC contracts for vaccine supply, including annual contracts for pediatric and adult vaccines. These IDVs include a $13.88 million contract for the Vaccines for Children (VFC) program, multiple adult vaccine contracts with annual values ranging from $1.6 to $1.8 million, and contracts covering approximately 12-20 different vaccine types. The IDVs span multiple years, typically with ultimate completion dates between 2022 and 2024, and enable federal agencies to efficiently procure essential medical products through competitive task order procedures without repetitive solicitations.
D48FNWJCJ5H5 325412
Not listed 2410 Grifols Wy, Los Angeles, CA 90032, USA
8/8/01 11/26/25 Sanofi Pasteur Inc.
Sanofi Pasteur Inc. is a foreign-owned, for-profit pharmaceutical manufacturer specializing in vaccine production and medical supplies, with a significant presence in the federal government contracting landscape. Registered in SAM.gov since 2002, the company is a major global supplier of vaccines and medical countermeasures to various U.S. federal agencies. As a manufacturer of goods, Sanofi Pasteur Inc. focuses on producing a wide range of vaccines, including seasonal and pandemic influenza vaccines, pediatric and adult immunizations, and critical public health vaccines. The company's manufacturing facility is located in Swiftwater, Pennsylvania, and it has established itself as a trusted vendor for multiple federal agencies seeking comprehensive vaccine and medical supply solutions.
Through its federal contract awards, Sanofi Pasteur Inc. has consistently provided a diverse array of medical products and services to numerous government agencies. The company has been awarded contracts primarily for vaccine supplies, including influenza vaccines, respiratory syncytial virus (RSV) vaccines, meningococcal vaccines, yellow fever vaccines, and COVID-19 vaccines. Key federal agencies purchasing from Sanofi Pasteur Inc. include the Centers for Disease Control and Prevention (CDC), Department of Veterans Affairs, Indian Health Service, Department of Defense, and the Department of Health and Human Services. These contracts span various program types, such as the Vaccines for Children (VFC) program, and include delivery orders for staff and inmate vaccinations at federal correctional institutions. The contract awards are typically firm fixed-price purchase orders or delivery orders, and notably, none of the reviewed awards utilized set-aside designations, indicating the company's competitive position in the federal marketplace.
Sanofi Pasteur Inc. holds multiple significant Indefinite Delivery Contracts (IDVs) across various federal agencies, with particularly extensive contracts with the CDC. These IDVs cover a broad range of vaccine procurement, including adult and pediatric vaccines for multiple fiscal years. Notable IDVs include a $2.196 billion contract for the Vaccines for Children program, a $47.55 million influenza vaccine contract with the Department of Veterans Affairs, and several CDC contracts for adult and pediatric vaccines with values ranging from $54 million to $158 million. The IDVs typically have performance periods of one to five years and are multiple-award or single-award contracts without set-aside designations. These contracts enable streamlined procurement of vaccines for diverse populations, supporting critical public health initiatives across federal, state, and tribal healthcare systems. The IDVs cover vaccines for numerous diseases, including influenza, COVID-19, hepatitis, measles, mumps, rubella, pneumococcal, meningococcal, and human papillomavirus, demonstrating Sanofi Pasteur's comprehensive vaccine manufacturing capabilities.
NCXBGGQ8YTU9 325414
Not listed 1 Discovery Dr, Swiftwater, PA 18370, USA
1/2/02 11/1/25 Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC, doing business as Merck, is a prominent pharmaceutical manufacturer and supplier to the U.S. federal government, registered in the System for Award Management (SAM) since 2011. As a for-profit corporate entity, Merck specializes in developing and supplying a wide range of pharmaceutical products, vaccines, and medical countermeasures to various federal agencies. The company is a subsidiary of Schering Plough Corporation and has established itself as a critical partner in supporting federal healthcare programs, public health initiatives, and medical research across multiple government sectors.
Through its federal contract awards, Merck has provided an extensive array of pharmaceutical products and vaccines to agencies including the Department of Veterans Affairs, Centers for Disease Control and Prevention, Department of Defense, and Department of Health and Human Services. The company's contract awards have encompassed critical medical treatments such as cancer drugs like Welireg (belzutifan), COVID-19 oral antivirals like molnupiravir, and various vaccines including MMR, VARIVAX, hepatitis, and pediatric immunizations. Notably, Merck has been awarded contracts for emergency medical supplies, vaccine storage and rotation services, and medical countermeasure development. None of Merck's federal contract awards have utilized set-aside designations, indicating open and competitive procurement processes across its federal contracting portfolio.
Merck holds several significant Indefinite Delivery Vehicles (IDVs) that demonstrate its strategic importance to federal healthcare procurement. The company has multiple high-value CDC contracts for pediatric and adult vaccines, including a $4.1 billion IDC for Vaccines for Children (VFC) program and an $87 million contract for adult vaccines. These IDVs cover vaccines for diseases such as hepatitis, pneumococcal, tetanus, measles, mumps, rubella, and human papillomavirus. Additionally, Merck has a $15 million Blanket Purchase Agreement with the National Acquisition Center for the drug Welireg and a $13 million CDC contract for vaccine storage and rotation services. The company also holds Other Transaction Agreements, such as a $39 million contract with the Joint PEO Chemical and Biological Defense for developing molnupiravir as an oral therapeutic, further showcasing its diverse capabilities in pharmaceutical research and development for federal agencies.
FCFDA78HKKG2 325412
Not listed 126 E Lincoln Ave, Rahway, NJ 07065, USA
3/9/11 4/29/26 Pfizer Inc.
Pfizer Inc. is a global pharmaceutical corporation headquartered in New York, registered in SAM.gov as a for-profit, corporate entity that serves as a prime federal contractor for various medical and pharmaceutical products. As a large manufacturer of goods, Pfizer provides critical healthcare supplies to multiple federal agencies, specializing in pharmaceuticals, vaccines, medical equipment, and injectable medications. The company holds significant federal contract vehicles and has demonstrated extensive capabilities in supplying medical products across government healthcare systems, including the Department of Veterans Affairs, Centers for Disease Control and Prevention, and Defense Logistics Agency.
Pfizer's federal contract awards primarily focus on delivering pharmaceutical products, including controlled substances, injectable medications, and critical medical supplies. The company's delivery orders span a wide range of pharmaceutical categories, such as antibiotics (Ceftriaxone), pain management medications (Morphine, Fentanyl), anti-nausea drugs (Ondansetron), hormone treatments (Estrogens), and emergency medical interventions like Naloxone for opioid overdose reversal. These contracts are predominantly with the Medical Supply Chain and Defense Logistics Agency Troop Support Medical, with contract values ranging from a few dollars to over $24,000. Importantly, none of Pfizer's recent federal contract awards utilize small business set-aside designations, reflecting the company's status as a large, established pharmaceutical manufacturer.
Pfizer holds two significant Indefinite Delivery Vehicle (IDV) contracts that underscore its critical role in federal healthcare procurement. The first is a $46,893,140 contract for Bevacizumab injections, serving multiple federal healthcare organizations including the Department of Veterans Affairs, Department of Defense, Bureau of Prisons, Indian Health Service, and Federal Health Care Center. The second is a $2,007,801,000 Vaccines for Children (VFC) program contract with the Centers for Disease Control and Prevention, which will provide pediatric vaccines to eligible children from April 1, 2025, through March 30, 2026. These IDVs demonstrate Pfizer's comprehensive capabilities in supplying complex pharmaceutical products across diverse government healthcare programs, with contracts that support everything from military medical readiness to public health immunization efforts.
MHBQULRMEEJ5 325412
Not listed 66 Hudson Blvd E, New York, NY 10001, USA
1/30/02 8/11/26